|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.58 EUR | -0.15% |
|
+55.61% | +155.40% |
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
Company Valuation: GENFIT
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 214.6 | 197 | 176 | 176.3 | 262.2 | 689.3 | - | - |
| Change | - | -8.19% | -10.69% | 0.17% | 48.73% | 162.93% | - | - |
| Enterprise Value (EV) 1 | 30.1 | 131.8 | 168.4 | 156.6 | 166.7 | 642.5 | 632.5 | 675.8 |
| Change | - | 337.75% | 27.79% | -6.98% | 6.41% | 285.52% | -1.56% | 6.86% |
| P/E | 3.51x | -8.27x | -6.1x | 118x | -3.06x | 72.5x | 91.5x | 12.6x |
| PBR | 2.55x | - | 2.59x | 2.54x | - | 8.76x | 10.5x | -56.1x |
| PEG | - | 0x | -0.3x | -1x | 0x | -1x | -4.4x | 0x |
| Capitalization / Revenue | 2.51x | 7.42x | 4.61x | 2.48x | 3.69x | 7.24x | 5.78x | 5.03x |
| EV / Revenue | 0.35x | 4.96x | 4.41x | 2.21x | 2.34x | 6.75x | 5.3x | 4.94x |
| EV / EBITDA | 0.87x | -5.18x | -6.75x | 31.3x | -3.22x | 22.9x | 10.4x | 9.37x |
| EV / EBIT | 0.95x | -4.83x | -6.33x | 47.7x | -37x | 22x | 10.4x | 9.42x |
| EV / FCF | 0.3x | - | -3.02x | 10.7x | -6.04x | -53.5x | 12,649x | 31.4x |
| FCF Yield | 330% | - | -33.2% | 9.35% | -16.6% | -1.87% | 0.01% | 3.18% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.23 | -0.48 | -0.58 | 0.03 | -1.72 | 0.1901 | 0.1506 | 1.098 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 85.58 | 26.57 | 38.18 | 70.94 | 71.12 | 95.2 | 119.3 | 136.9 |
| EBITDA 1 | 34.56 | -25.46 | -24.93 | 5.005 | -51.79 | 28.08 | 60.67 | 72.14 |
| EBIT 1 | 31.82 | -27.29 | -26.58 | 3.281 | -4.5 | 29.22 | 61 | 71.77 |
| Net income 1 | 67.26 | -23.72 | -28.89 | 1.507 | -85.97 | 18.63 | 0.0333 | 22.07 |
| Net Debt 1 | -184.5 | -65.28 | -7.611 | -19.66 | -95.52 | -46.87 | -56.87 | -13.51 |
| Reference price 2 | 4.32 | 3.97 | 3.54 | 3.54 | 5.26 | 13.78 | 13.78 | 13.78 |
| Nbr of stocks (in thousands) | 49,727 | 49,655 | 49,712 | 49,865 | 49,795 | 50,024 | - | - |
| Announcement Date | 07/04/22 | 13/04/23 | 04/04/24 | 24/04/25 | 02/04/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.02x | 6.15x | 19.02x | 0.94% | 50.44B | |
| -23.93x | 350.56x | -22.64x | -.--% | 40.63B | |
| 25.43x | 2.81x | 12.14x | -.--% | 34.88B | |
| 46.36x | 4.58x | 29.24x | -.--% | 33.67B | |
| 26.73x | 7.84x | 19.68x | 0.43% | 26.29B | |
| 31.59x | 5.09x | 23.2x | -.--% | 15.29B | |
| -17.76x | 11.63x | -17.23x | -.--% | 10.62B | |
| 23.89x | 2.03x | 8.94x | 1.12% | 13.74B | |
| Average | 18.42x | 48.84x | 9.04x | 0.31% | 28.2B | |
| Weighted average by Cap. | 20.25x | 67.57x | 10.01x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
- Valuation GENFIT
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
